Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.

Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, Kardinal CG, Knost JA, Tirona MT, Addo F, Morton RF, Michalak JC, Schaefer PL, Porter PA, Stella PJ.

J Clin Oncol. 2003 Mar 1;21(5):914-20.

PMID:
12610193
2.

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL.

Mayo Clin Proc. 2007 Feb;82(2):186-95.

PMID:
17290726
3.

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.

Clin Ther. 2001 May;23(5):744-52.

PMID:
11394732
4.

Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study.

Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, O'Connor K.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):111-8. doi: 10.1016/j.drugalcdep.2011.03.005. Epub 2011 Apr 19.

5.

A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.

Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB.

Arch Gen Psychiatry. 2009 Nov;66(11):1253-62. doi: 10.1001/archgenpsychiatry.2009.142. Erratum in: Arch Gen Psychiatry. 2010 Jan;67(1):77. Dosage error in article text.

6.

A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders.

Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M.

J Clin Psychopharmacol. 2008 Dec;28(6):660-6. doi: 10.1097/JCP.0b013e31818ad7d6.

7.

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB.

N Engl J Med. 1999 Mar 4;340(9):685-91.

8.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
9.

Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers.

Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, Samuels D, Levin SK, Green S, Schatzberg AF.

J Consult Clin Psychol. 2004 Aug;72(4):729-35.

PMID:
15301658
10.

Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.

Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL.

Ann Intern Med. 2009 Apr 7;150(7):447-54.

PMID:
19349630
11.

A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics.

Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA.

Nicotine Tob Res. 2009 Jul;11(7):859-67. doi: 10.1093/ntr/ntp077. Epub 2009 May 29.

12.

Smoking cessation treatment in a real-life setting: the Greek experience.

Rovina N, Nikoloutsou I, Dima E, Michailidou M, Roussos C, Gratziou C.

Ther Adv Respir Dis. 2007 Dec;1(2):93-104. doi: 10.1177/1753465807085799.

PMID:
19124351
13.

Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm.

Rose JE, Behm FM.

Nicotine Tob Res. 2017 Aug 1;19(8):999-1002. doi: 10.1093/ntr/ntw283.

14.

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.

J Clin Psychopharmacol. 2007 Aug;27(4):380-6.

PMID:
17632223
15.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
16.

Targeting smokers at increased risk for relapse: treating women and those with a history of depression.

Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Jamerson B, Fiore MC, Baker TB.

Nicotine Tob Res. 2003 Feb;5(1):99-109.

PMID:
12745511
17.

Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.

Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G.

Addiction. 2004 Sep;99(9):1206-18.

PMID:
15317642
18.

The effect of five smoking cessation pharmacotherapies on smoking cessation milestones.

Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB.

J Consult Clin Psychol. 2011 Feb;79(1):34-42. doi: 10.1037/a0022154.

19.
20.

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD.

Ann Intern Med. 2001 Sep 18;135(6):423-33.

PMID:
11560455

Supplemental Content

Support Center